期刊
FRONTIERS IN IMMUNOLOGY
卷 5, 期 -, 页码 1-6出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fimmu.2014.00183
关键词
dengue virus; prospective cohort studies; lessons; vaccine; development
类别
资金
- Office of the Provincial Public Health
- Kamphaeng Phet Province
- National Institutes of Health (NIH) [P01 AI034533, R01 GM083224-01]
- Military Infectious Diseases Research Program (MIDRP)
- United States Army Medical Research and Materiel Command, Ft Detrick, MD, USA
Dengue virus (DENV) continues to spread globally and is a major cause of morbidity and mortality. Currently, there is no antiviral treatment to diminish severe illness or a vaccine to induce protection from infection. An effective dengue vaccine that protects against all four DENV serotypes is a high priority for endemic countries and several candidates are in development by various United States Federal Agencies and private pharmaceutical companies. Challenges faced by dengue vaccine developers include creating tetravalent formulations that provide tetravalent protection, the lack of a correlate of protective immunity, a changing viral landscape as DENV evolves, and a complex viral-host pathogenesis that can result in a spectrum of illness from subclinical infection to severe hemorrhagic fever. There have been a number of long-term prospective studies on DENV transmission and dengue severity that have provided invaluable information on DENV epidemiology and pathogenesis of this disease. In this section, we will review the critical lessons learned from these studies and their application for dengue vaccine development.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据